Pembrolizumab versus Ipilimumab in Advanced Melanoma
Work
Year: 2015
Type: article
Abstract: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has an... more
Source: New England Journal of Medicine
Institutions Université Paris-Sud, Sheba Medical Center, Mater Hospital, Target (United States), Breast Cancer Research Foundation +16 more
Cites: 26
Cited by: 5,322
Related to: 10
FWCI: 331.8
Citation percentile (by year/subfield): 100
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: bronze